Japan Drug Makers Join Trend Of Outsourcing Trials, Other Work
This article was originally published in PharmAsia News
Japanese drug makers are joining the trend of outsourcing clinical trials to other countries. Daiichi Sankyo is moving its first trials to India beginning next month even though foreign tests cannot be used for drug approvals in Japan. But Daiichi Sankyo says trials are cheaper in India where the population is adopting Western eating habits, making them more suitable for drugs to be marketed in Western countries. Astellas Pharma plans trials in South Korea and Eisai is exporting clinical research work to Singapore and development in other Asian nations, particularly China and India. Smaller Japanese pharmas also are looking to join the trend. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - Japanese pharmaceutical manufacturers are diversifying their Phase III clinical trials away from Japan to establish development footholds into fast-developing East Asia and other regions where costs are low and trial patients can be secured with ease
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.